Table II.
Description Of SARS-Cov-2 positive survivors and nonsurvivors (unmatched cohort)
| SARS-CoV-2 positive patients Survivors n = 135 |
SARS-CoV-2 positive patients Nonsurvivors n = 26 |
P value | |
|---|---|---|---|
| Patient characteristics | |||
| Age category–no (%) | <.001 | ||
| <50 y | 14 (10.4) | 0 (0.0) | |
| 50–<70 y | 49 (36.6) | 2 (7.7) | |
| ≥70 y | 71 (53.0) | 24 (92.3) | |
| Female sex–no (%) | 62 (45.9) | 10 (38.5) | .63 |
| BMI–no (%) | .93 | ||
| <18.5 | 5 (3.7) | 2 (7.7) | |
| 18.5–<25 | 40 (29.6) | 9 (34.6) | |
| 25–<30 | 40 (29.6) | 6 (23.1) | |
| 30–<35 | 26 (19.3) | 6 (23.1) | |
| 35–<40 | 10 (7.4) | 2 (7.7) | |
| ≥40 | 4 (3.0) | 1 (3.8) | |
| Current smoker–no (%) | 14 (10.4) | 4 (15.4) | .71 |
| Diabetes–no (%) | 32 (23.7) | 12 (46.2) | .04 |
| Hypertension–no (%) | 64 (47.4) | 16 (61.5) | |
| Congestive heart failure–no (%) | 7 (5.2) | 6 (23.1) | |
| Myocardial infarct–no (%) | 13 (9.6) | 8 (30.3) | .27 |
| Peripheral vascular disease–no (%) | 16 (11.9) | 10 (38.5) | .002 |
| Chronic pulmonary disease–no (%) | 14 (10.4) | 6 (23.1) | .14 |
| CVA–no (%) | 18 (13.3) | 6 (23.1) | .33 |
| Chronic renal disease–no (%) | 15 (11.1) | 7 (26.9) | .07 |
| Cancer–no (%) | 26 (19.3) | 4 (15.4) | .85 |
| Transplant–no (%) | 0 (0.0) | 1 (3.8) | 1.00 |
| Immunosuppression–no (%) | 9 (6.7) | 1 (3.8) | .92 |
| ECOG score | .002 | ||
| 0–1 | 84 (62.2) | 9 (34.6) | |
| 2 | 22 (16.3) | 4 (15.4) | |
| 3–4 | 19 (14.1) | 11 (42.3) | |
| Charlson comorbidity index–median (IQR) | 4.0 (2.0–6.0) | 6.5 (4.0–8.9) | .001 |
| Surgery characteristics | |||
| ASA classification–no (%) | .02 | ||
| I–II | 56 (41.5) | 4 (15.4) | |
| III–IV | 75 (55.6) | 22 (84.6) | |
| Anesthesia–no (%) | .79 | ||
| General | 100 (74.1) | 18 (69.2) | |
| Other (including spinal) | 35 (25.9) | 8 (30.8) | |
| Type of operation–no (%) | 1.00 | ||
| Elective | 73 (54.1) | 14 (53.8) | |
| Emergency | 61 (45.2) | 12 (46.2) | |
| Surgical risk score–no (%) | .06 | ||
| 1–2 | 39 (38.9) | 3 (11.5) | |
| 3 | 47 (34.8) | 17 (65.4) | |
| 4 | 31 (23.0) | 5 (19.2) | |
| 5 | 9 (6.7) | 1 (3.8) | |
| SARS-CoV-2 characteristics | |||
| Timing of diagnosis–no (%) | .001 | ||
| Preoperative | 67 (49.6) | 2 (7.7) | |
| Postoperative | 68 (50.4) | 24 (92.3) | |
| Symptomatology–no (%) | 1.00 | ||
| Asymptomatic | 9 (6.7) | 2 (7.7) | |
| ≥1 symptom | 117 (86.7) | 23 (88.5) | |
BMI, body mass index; CVA, cerebrovascular accident; ECOG, Eastern Cooperative Oncology Group.